Hepatitis C virus

Summary

Alias: hepatitis C virus HCV, human hepatitis C virus, human hepatitis C virus HCV, human hepatitis virus C HCV, post-transfusion hepatitis non A non B virus, HCV, Hepatitis C, human hepatitis virus HCV

Top Publications

  1. pmc Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies
    Joe Grove
    Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom
    J Virol 82:12020-9. 2008
  2. pmc Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding
    Katharina B Rothwangl
    Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Virol J 5:46. 2008
  3. doi Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α
    Troels K H Scheel
    Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark
    Gastroenterology 140:1032-42. 2011
  4. pmc Proteasomal turnover of hepatitis C virus core protein is regulated by two distinct mechanisms: a ubiquitin-dependent mechanism and a ubiquitin-independent but PA28gamma-dependent mechanism
    Ryosuke Suzuki
    Department of Virology II, National Institute of Infectious Diseases, Tokyo 162 8640, Japan
    J Virol 83:2389-92. 2009
  5. doi A molecular chaperone glucose-regulated protein 94 blocks apoptosis induced by virus infection
    Song Hee Lee
    PBC, Department of Life Science, Pohang University of Science and Technology, Hyoja Dong, Pohang, Kyungbuk, Korea
    Hepatology 47:854-66. 2008
  6. pmc Hepatitis C virus NS5B polymerase exhibits distinct nucleotide requirements for initiation and elongation
    Eric Ferrari
    Department of Virology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    J Biol Chem 283:33893-901. 2008
  7. doi Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients
    Barbara Bartolini
    L Spallanzani National institute for infectious diseases, Via Portuense 292, 00149 Rome, Italy
    Virus Res 177:205-8. 2013
  8. doi HCV NS3/4A protein activates HIV-1 transcription from its long terminal repeat
    Xiaoyun Wu
    State Key Laboratory of Virology and the Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, PR China
    Virus Res 135:155-60. 2008
  9. pmc The protease domain increases the translocation stepping efficiency of the hepatitis C virus NS3-4A helicase
    Vaishnavi Rajagopal
    Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854, USA
    J Biol Chem 285:17821-32. 2010
  10. ncbi Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1
    Alessandra Spaziani
    Laboratory of Clinical Hepatology, Department of Internal Medicine, University of L Aquila, 67100 L Aquila, Italy
    J Biol Chem 281:10983-9. 2006

Research Grants

  1. GUANGXIANG GEORGE LUO; Fiscal Year: 2016
  2. GUANGXIANG GEORGE LUO; Fiscal Year: 2014
  3. Effects of Ethanol on Proteasome-HCV Core Protein Interactions
    NATALIA ALEKSANDR OSNA; Fiscal Year: 2010
  4. Hepatitis C and Tumor Suppressors in Hepatocellular
    Stanley M Lemon; Fiscal Year: 2011
  5. Steven A Weinman; Fiscal Year: 2016
  6. Warren N Schmidt; Fiscal Year: 2016
  7. Urtzi Garaigorta; Fiscal Year: 2015
  8. Peter Sarnow; Fiscal Year: 2016
  9. Swati Joshi-Barve; Fiscal Year: 2014
  10. Mechanisms of Cellular Immune Dysfunction in Patients with Hepatitis C Virus and
    Kyong Mi Chang; Fiscal Year: 2013

Patents

  1. 2'-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION
  2. Hepatitis C virus core targeting trans-splicing ribozyme and use thereof
  3. NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF
  4. FLAVIVIRUS REPLICONS
  5. A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW& AND HIGH MOLECULAR WEIGHT COMPOUNDS
  6. A Pharmaceutical composition for treating and/or preventing Hepatitis C
  7. ANTI-HEPATITIS C ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF
  8. FLAVIVIRUS REPLICONS
  9. OPTIMIZED HCV FULL-LENGTH INFECTIOUS CELL CULTURE SYSTEMS AND APPLICATIONS THEREOF
  10. NOVEL FUSION PROTEINS AND USE THEREOF FOR PREPARING HEPATITIS C VACCINES

Detail Information

Publications287 found, 100 shown here

  1. pmc Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies
    Joe Grove
    Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, United Kingdom
    J Virol 82:12020-9. 2008
    b>Hepatitis C virus (HCV) infection is dependent on at least three coreceptors: CD81, scavenger receptor BI (SR-BI), and claudin-1. The mechanism of how these molecules coordinate HCV entry is unknown...
  2. pmc Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding
    Katharina B Rothwangl
    Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Virol J 5:46. 2008
    b>Hepatitis C virus (HCV) encodes two transmembrane glycoproteins E1 and E2 which form a heterodimer. E1 is believed to mediate fusion while E2 has been shown to bind cellular receptors including CD81...
  3. doi Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α
    Troels K H Scheel
    Copenhagen Hepatitis C Program, Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark
    Gastroenterology 140:1032-42. 2011
    Heterogeneity in the hepatitis C virus (HCV) protein NS5A influences its sensitivity to interferon-based therapy. Furthermore, NS5A is an important target for development of HCV-specific inhibitors...
  4. pmc Proteasomal turnover of hepatitis C virus core protein is regulated by two distinct mechanisms: a ubiquitin-dependent mechanism and a ubiquitin-independent but PA28gamma-dependent mechanism
    Ryosuke Suzuki
    Department of Virology II, National Institute of Infectious Diseases, Tokyo 162 8640, Japan
    J Virol 83:2389-92. 2009
    We have previously reported on the ubiquitylation and degradation of hepatitis C virus core protein. Here we demonstrate that proteasomal degradation of the core protein is mediated by two distinct mechanisms...
  5. doi A molecular chaperone glucose-regulated protein 94 blocks apoptosis induced by virus infection
    Song Hee Lee
    PBC, Department of Life Science, Pohang University of Science and Technology, Hyoja Dong, Pohang, Kyungbuk, Korea
    Hepatology 47:854-66. 2008
    The hepatitis C virus (HCV) E2 protein has been shown to block apoptosis and has been suggested to facilitate persistent infection of the virus...
  6. pmc Hepatitis C virus NS5B polymerase exhibits distinct nucleotide requirements for initiation and elongation
    Eric Ferrari
    Department of Virology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    J Biol Chem 283:33893-901. 2008
    The hepatitis C virus (HCV) NS5B protein is an RNA-dependent RNA polymerase (RdRp) essential for replication of the viral RNA genome. Purified NS5B has been reported to exhibit multiple activities in vitro...
  7. doi Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients
    Barbara Bartolini
    L Spallanzani National institute for infectious diseases, Via Portuense 292, 00149 Rome, Italy
    Virus Res 177:205-8. 2013
    b>HCV quasispecies variability represents the background for the selection of mutations and for the development of drug resistance...
  8. doi HCV NS3/4A protein activates HIV-1 transcription from its long terminal repeat
    Xiaoyun Wu
    State Key Laboratory of Virology and the Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan 430072, PR China
    Virus Res 135:155-60. 2008
    ..S. are also infected with the hepatitis C virus (HCV)...
  9. pmc The protease domain increases the translocation stepping efficiency of the hepatitis C virus NS3-4A helicase
    Vaishnavi Rajagopal
    Department of Biochemistry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854, USA
    J Biol Chem 285:17821-32. 2010
    b>Hepatitis C virus (HCV) NS3 protein has two enzymatic activities of helicase and protease that are essential for viral replication. The helicase separates the strands of DNA and RNA duplexes using the energy from ATP hydrolysis...
  10. ncbi Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1
    Alessandra Spaziani
    Laboratory of Clinical Hepatology, Department of Internal Medicine, University of L Aquila, 67100 L Aquila, Italy
    J Biol Chem 281:10983-9. 2006
    Some hepatitis C virus (HCV) proteins, including core protein, deregulate the cell cycle of infected cells, thereby playing an important role in the viral pathogenesis of HCC...
  11. pmc Interactions between viral nonstructural proteins and host protein hVAP-33 mediate the formation of hepatitis C virus RNA replication complex on lipid raft
    Lu Gao
    Department of Molecular Microbiology and Immunology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    J Virol 78:3480-8. 2004
    The lipid raft membrane has been shown to be the site of hepatitis C virus (HCV) RNA replication. The mechanism of formation of the replication complex is not clear...
  12. pmc Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein
    Allan G N Angus
    MRC Virology Unit, Institute of Virology, University of Glasgow, Church Street, Glasgow G11 5JR, UK
    J Gen Virol 91:122-32. 2010
    The cellular DEAD-box protein DDX3 was recently shown to be essential for hepatitis C virus (HCV) replication. Prior to that, we had reported that HCV core binds to DDX3 in yeast-two hybrid and transient transfection assays...
  13. pmc The acidic domain of hepatitis C virus NS4A contributes to RNA replication and virus particle assembly
    Tung Phan
    Section of Microbial Pathogenesis, Yale University School of Medicine, 354C BCMM, 295 Congress Ave, New Haven, CT 06536, USA
    J Virol 85:1193-204. 2011
    b>Hepatitis C virus NS3-4A is a membrane-bound enzyme complex that exhibits serine protease, RNA helicase, and RNA-stimulated ATPase activities...
  14. ncbi Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins
    Stephanie T Shi
    Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA
    Virology 292:198-210. 2002
    The nonstructural protein 5A (NS5A) of the hepatitis C virus (HCV) has been shown to interact with a variety of cellular proteins and implicated in the regulation of cell growth, interferon resistance, and other cellular signaling ..
  15. pmc A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase
    Sreedhar Chinnaswamy
    Department of Biochemistry and Biophysics, Texas A and M University, College Station, TX 77843 2128, USA
    J Biol Chem 283:20535-46. 2008
    Mutational analysis of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp) template channel identified two residues, Trp(397) and His(428), which are required for de novo initiation but not for extension from a primer...
  16. pmc Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity
    Zhen Yong Keck
    Department of Pathology, Stanford University, Stanford, California 94305, USA
    J Virol 83:6149-60. 2009
    Broadly neutralizing antibodies are commonly present in the sera of patients with chronic hepatitis C virus (HCV) infection...
  17. ncbi A genomic approach of the hepatitis C virus generates a protein interaction map
    M Flajolet
    INSERM U163, Institut Pasteur, Paris, France
    Gene 242:369-79. 2000
    The hepatitis C virus (HCV) causes severe liver disease, including liver cancer...
  18. pmc Subcellular localization and topology of the p7 polypeptide of hepatitis C virus
    Séverine Carrère-Kremer
    CNRS FRE2369, Institut de Biologie de Lille Institut Pasteur de Lille, 59021 Lille Cedex, France
    J Virol 76:3720-30. 2002
    Although biological and biochemical data have been accumulated on most hepatitis C virus proteins, the structure and function of the 63-amino-acid p7 polypeptide of this virus have never been investigated...
  19. pmc Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein
    Timothy L Tellinghuisen
    Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, 1230 York Avenue, Box 64, New York, NY 10065, USA
    J Virol 82:1073-83. 2008
    The NS5A protein of hepatitis C virus (HCV) plays an important but undefined role in viral RNA replication...
  20. pmc Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase
    Rudolf K F Beran
    Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520, USA
    J Biol Chem 283:29929-37. 2008
    ..a multifunctional enzyme possessing serine protease, NTPase, and RNA unwinding activities that are required for hepatitis C viral (HCV) replication...
  21. pmc Characterization of hepatitis C virus core protein multimerization and membrane envelopment: revelation of a cascade of core-membrane interactions
    Li Shuang Ai
    Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 11490, Taiwan, Republic of China
    J Virol 83:9923-39. 2009
    The molecular basis underlying hepatitis C virus (HCV) core protein maturation and morphogenesis remains elusive. We characterized the concerted events associated with core protein multimerization and interaction with membranes...
  22. ncbi Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease
    Josephine C Ferreon
    Department of Microbiology and Immunology, Center for Hepatitis Research, Institute for Human Infections and Immunity, University of Texas Medical Branch at Galveston, Galveston, Texas 77555 1019, USA
    J Biol Chem 280:20483-92. 2005
    Persistent infections with hepatitis C virus (HCV) are a major cause of liver disease and reflect its ability to disrupt virus-induced signaling pathways activating cellular antiviral defenses...
  23. ncbi Risk of hepatocellular carcinoma and secondary structure of hepatitis C virus (HCV) NS3 protein amino-terminus, in patients infected with HCV subtype 1b
    Yuko Nishise
    Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata 990 9585, Japan
    J Infect Dis 196:1006-9. 2007
    ..chronic hepatitis C, to determine whether the secondary structure of the amino-terminal 120 residues of the hepatitis C virus (HCV) NS3 protein is associated with an increased risk of development of hepatocellular carcinoma (HCC)...
  24. pmc Identification of new functional regions in hepatitis C virus envelope glycoprotein E2
    Anna Albecka
    Institut Pasteur de Lille, Center for Infection and Immunity of Lille, F 59019 Lille, France
    J Virol 85:1777-92. 2011
    Little is known about the structure of the envelope glycoproteins of hepatitis C virus (HCV)...
  25. ncbi Hepatitis C virus core protein interacts with a human DEAD box protein DDX3
    A M Owsianka
    Medical Research Council Virology Unit, Church Street, Glasgow, G11 5JR, United Kingdom
    Virology 257:330-40. 1999
    Several studies have implicated hepatitis C virus (HCV) core in influencing the expression of host genes...
  26. ncbi The NS5A protein of hepatitis C virus is a zinc metalloprotein
    Timothy L Tellinghuisen
    Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, New York, New York 10021, USA
    J Biol Chem 279:48576-87. 2004
    The NS5A protein of hepatitis C virus is believed to be an integral part of the viral replicase. Despite extensive investigation, the role of this protein remains elusive...
  27. pmc Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation
    Ravi Jhaveri
    Division of Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 197:283-91. 2008
    Steatosis is a common histological finding and a poor prognostic indicator in patients with hepatitis C virus (HCV) infection...
  28. doi HCV core protein interacts with Dicer to antagonize RNA silencing
    Weixian Chen
    The Institute for Viral Hepatitis, Key Laboratory of Molecular Biology on Infectious Diseases of the Ministry of Education, Chongqing Medical University, Chongqing, 400016, China
    Virus Res 133:250-8. 2008
    ..Here, we report that the core protein of Hepatitis C virus (HCV) acts as a potent suppressor of RNA silencing (SRS)...
  29. ncbi Homotypic interaction and multimerization of hepatitis C virus core protein
    M Matsumoto
    Howard Hughes Medical Institute, University of Southern California School of Medicine, Los Angeles, California, 90033, USA
    Virology 218:43-51. 1996
    b>Hepatitis C virus (HCV) core protein constitutes a viral nucleocapsid and may possess multiple functions. In this study, we demonstrated the homotypic interaction and multimerization of HCV core protein in vitro and in vivo...
  30. ncbi Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A
    P Gallinari
    Istituto di Ricerche di Biologia Molecolare P Angeletti, Rome, Italy
    Biochemistry 38:5620-32. 1999
    The hepatitis C virus nonstructural 3 protein (NS3) possesses a serine protease activity in the N-terminal one-third, whereas RNA-stimulated NTPase and helicase activities reside in the C-terminal portion...
  31. pmc Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2
    A Higginbottom
    Department of Molecular Biology, University of Sheffield, Sheffield S10 2UH, United Kingdom
    J Virol 74:3642-9. 2000
    Human CD81 has been previously identified as the putative receptor for the hepatitis C virus envelope glycoprotein E2...
  32. pmc Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection
    A Meola
    Istituto di Ricerche di Biologia Molecolare P Angeletti IRBM, Pomezia Roma, Italy
    J Virol 74:5933-8. 2000
    b>Hepatitis C virus (HCV) glycoprotein E2 binds to human cells by interacting with the CD81 molecule, which has been proposed to be the viral receptor...
  33. ncbi Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity
    Yukihiro Shirota
    Department of Molecular Oncology, Kanazawa University, 13 1 Takara machi, Kanazawa 920 0934, Ishikawa, Japan
    J Biol Chem 277:11149-55. 2002
    b>Hepatitis C virus (HCV) NS5B is RNA-dependent RNA polymerase (RdRP), the essential catalytic enzyme for HCV replication...
  34. ncbi HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis
    Keng Hsin Lan
    Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital and National Yang Ming University School of Medicine, Taipei 11217, Taiwan, Republic of China
    Oncogene 21:4801-11. 2002
    b>Hepatitis C virus (HCV) causes a persistent infection, chronic hepatitis and hepatocellular carcinoma. HCV NS5A, one of non-structural proteins of HCV, was suggested to play a role in oncogenic transformation...
  35. ncbi Identification and characterization of amphiphysin II as a novel cellular interaction partner of the hepatitis C virus NS5A protein
    Birgit Zech
    Axxima Pharmaceuticals AG, Am Klopferspitz 19, 82152 Martinsried, Germany
    J Gen Virol 84:555-60. 2003
    The hepatitis C virus (HCV) NS5A protein is highly phosphorylated by cellular protein kinases...
  36. ncbi Physical and functional interaction between HCV core protein and the different p73 isoforms
    Anna Alisi
    Fondazione Andrea Cesalpino, I Clinica Medica, V le del Policlinico 155, 00161 Roma, Italy
    Oncogene 22:2573-80. 2003
    b>Hepatitis C virus (HCV) core protein is a structural viral protein that packages the viral genomic RNA. In addition to this function, HCV core also modulates a number of cellular regulatory functions...
  37. ncbi The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity
    Andrew Macdonald
    Division of Microbiology, School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, UK
    J Gen Virol 85:721-9. 2004
    The hepatitis C virus (HCV) non-structural NS5A protein has been shown to associate with a variety of cellular signalling proteins...
  38. ncbi Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry
    Heidi E Drummer
    St Vincent s Institute of Medical Research, 41 Victoria Pde Fitzroy, Victoria Australia 3065
    J Biol Chem 279:30066-72. 2004
    The E1 and E2 glycoproteins of hepatitis C virus form a noncovalently associated heterodimer that mediates viral entry...
  39. ncbi A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals
    Fredrik Thoren
    Department of Clinical Virology, Goteborg University, Guldhedsgatan 10B, S 413 46 Goteborg, Sweden
    J Leukoc Biol 76:1180-6. 2004
    The persistent infection caused by hepatitis C virus (HCV) is presumably explained by a deficient immune response to the infection, but the basis for the inefficiency of immune-mediated virus eradication is not known in detail...
  40. ncbi Further studies on hepatitis C virus NS5A-SH3 domain interactions: identification of residues critical for binding and implications for viral RNA replication and modulation of cell signalling
    Andrew Macdonald
    School of Biochemistry and Microbiology and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK
    J Gen Virol 86:1035-44. 2005
    The NS5A protein of hepatitis C virus has been shown to interact with a subset of Src homology 3 (SH3) domain-containing proteins...
  41. ncbi Modulation of the transforming growth factor-beta signal transduction pathway by hepatitis C virus nonstructural 5A protein
    Soo Ho Choi
    Ilsong Institute of Life Science, Hallym University, 1 Ockcheon dong, Chuncheon 200 702, Korea
    J Biol Chem 281:7468-78. 2006
    ..b>Hepatitis C virus (HCV) infection often leads to cirrhosis and hepatocellular carcinoma...
  42. ncbi Structural determinants that target the hepatitis C virus core protein to lipid droplets
    Steeve Boulant
    Medical Research Council Virology Unit, Institute of Virology, Church St, Glasgow G11 5JR, Scotland, United Kingdom
    J Biol Chem 281:22236-47. 2006
    b>Hepatitis C virus core protein is targeted to lipid droplets, which serve as intracellular storage organelles, by its C-terminal domain, termed D2...
  43. pmc The alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation
    Manuela Quintavalle
    Istituto di Ricerche di Biologia Molecolare P Angeletti, 00040 Pomezia Roma, Italy
    J Virol 80:11305-12. 2006
    b>Hepatitis C virus (HCV) has been the subject of intensive studies for nearly two decades. Nevertheless, some aspects of the virus life cycle are still a mystery...
  44. pmc Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90
    Toru Okamoto
    Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
    EMBO J 25:5015-25. 2006
    b>Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) is a component of viral replicase and is well known to modulate the functions of several host proteins...
  45. pmc E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein
    Masayuki Shirakura
    Department of Virology II, National Institute of Infectious Diseases, 1 23 1 Toyama, Shinjuku ku, Tokyo 162 8640, Japan
    J Virol 81:1174-85. 2007
    b>Hepatitis C virus (HCV) core protein is a major component of viral nucleocapsid and a multifunctional protein involved in viral pathogenesis and hepatocarcinogenesis...
  46. ncbi Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core
    Candice Jackel-Cram
    Vaccine and Infectious Disease Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    J Hepatol 46:999-1008. 2007
    b>Hepatitis C virus genotype-3a (HCV-3a) is directly linked to steatosis development. We studied the effects of HCV-3a core protein on the promoter activity of fatty acid synthase (FAS), a major enzyme involved in de novo lipid synthesis.
  47. ncbi [Expression and preliminary study of HCV F protein gene]
    Chun mei Jiang
    Department of Epidemiology and Biostatistics, Nanjing Medical University, Nanjing 210029, China
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23:134-7. 2007
    To express HCV F protein gene fragment in E.coli and detect if there is its antibody in HCV patients.
  48. pmc The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein
    François Helle
    Institut de Biologie de Lille UMR8161, CNRS, Université Lille I and II and Institut Pasteur de Lille, Lille, France
    J Virol 81:8101-11. 2007
    b>Hepatitis C virus (HCV) envelope glycoproteins are highly glycosylated, with up to 5 and 11 N-linked glycans on E1 and E2, respectively...
  49. pmc Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines
    Takayuki Abe
    Department of Molecular Virology, Graduate School of Medicine, Osaka University, Osaka, Japan
    J Virol 81:8953-66. 2007
    b>Hepatitis C virus (HCV) infection induces a wide range of chronic liver injuries; however, the mechanism through which HCV evades the immune surveillance system remains obscure...
  50. pmc A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication
    Ella H Sklan
    Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR 3115A, 269 Campus Drive, Palo Alto, CA 94305 5187, USA
    J Virol 81:11096-105. 2007
    b>Hepatitis C virus (HCV) is an important cause of liver disease worldwide. Current therapies are inadequate for most patients...
  51. ncbi The serine protease domain of hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate
    Rudolf K F Beran
    Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520, USA
    J Biol Chem 282:34913-20. 2007
    Nonstructural (NS) protein 3 is a DEXH/D-box motor protein that is an essential component of the hepatitis C viral (HCV) replicative complex...
  52. ncbi A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals
    Sandra Franco
    Fundacio irsiCaixa, Universitat Autonoma de Barcelona UAB, Spain
    Virus Res 131:260-70. 2008
    The hepatitis C virus (HCV) NS3/4A protease acts as an antagonist of virus-induced interferon (IFN) regulatory factor (IRF)-3 activation and IFN-beta expression...
  53. doi A screening method for identifying disruptions in interferon signaling reveals HCV NS3/4a disrupts Stat-1 phosphorylation
    Karla J Helbig
    Infectious Diseases Laboratories, Institute of Medical and Veterinary Science, Adelaide, SA 5000, Australia
    Antiviral Res 77:169-76. 2008
    ..an efficient screening method to identify viral proteins and their ability to block Jak-Stat signaling using hepatitis C virus (HCV) as an example...
  54. pmc Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex
    Volker Brass
    Department of Medicine II, University of Freiburg, D 79106 Freiburg, Germany
    Proc Natl Acad Sci U S A 105:14545-50. 2008
    b>Hepatitis C virus (HCV) NS3-4A is a membrane-associated multifunctional protein harboring serine protease and RNA helicase activities...
  55. pmc Trans-complementation of an NS2 defect in a late step in hepatitis C virus (HCV) particle assembly and maturation
    Minkyung Yi
    Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX, USA
    PLoS Pathog 5:e1000403. 2009
    Recent studies using cell culture infection systems that recapitulate the entire life cycle of hepatitis C virus (HCV) indicate that several nonstructural viral proteins, including NS2, NS3, and NS5A, are involved in the process of viral ..
  56. pmc Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes
    Tung Phan
    Section of Microbial Pathogenesis, Yale University School of Medicine, 295 Congress Ave, New Haven, CT 06536, USA
    J Virol 83:8379-95. 2009
    The hepatitis C virus NS2 protein has been recently implicated in virus particle assembly...
  57. pmc Genetic analysis of the carboxy-terminal region of the hepatitis C virus core protein
    Martina Kopp
    Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA
    J Virol 84:1666-73. 2010
    b>Hepatitis C virus (HCV) is a liver-tropic pathogen with severe health consequences for infected individuals...
  58. pmc Secondary structure, dynamics, and architecture of the p7 membrane protein from hepatitis C virus by NMR spectroscopy
    Gabriel A Cook
    Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA
    Biochim Biophys Acta 1808:1448-53. 2011
    P7 is a small membrane protein that is essential for the infectivity of hepatitis C virus. Solution-state NMR experiments on p7 in DHPC micelles, including hydrogen/deuterium exchange, paramagnetic relaxation enhancement and bicelle 'q-..
  59. pmc Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding
    Keith P Romano
    Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Proc Natl Acad Sci U S A 107:20986-91. 2010
    b>Hepatitis C virus infects an estimated 180 million people worldwide, prompting enormous efforts to develop inhibitors targeting the essential NS3/4A protease...
  60. pmc Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes
    Kenneth A Stapleford
    Section of Microbial Pathogenesis, Yale University School of Medicine, 295 Congress Ave, New Haven, Connecticut 06536, USA
    J Virol 85:1706-17. 2011
    The hepatitis C virus (HCV) NS2 protein is essential for particle assembly, but its function in this process is unknown...
  61. pmc The ESCRT system is required for hepatitis C virus production
    Yasuo Ariumi
    Department of Tumor Virology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
    PLoS ONE 6:e14517. 2011
    Recently, lipid droplets have been found to be involved in an important cytoplasmic organelle for hepatitis C virus (HCV) production. However, the mechanisms of HCV assembly, budding, and release remain poorly understood...
  62. doi Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCV core protein
    Maria Ripoli
    Gastroenterology Unit, IRCCS Casa Sollievo della Sofferenza Hospital, Viale dei Cappuccini n 1, 71013 San Giovanni Rotondo FG, Italy
    Virus Res 160:74-81. 2011
    The mechanisms of hepatocarcinogenesis induced by hepatitis C virus remain unclear...
  63. pmc Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis
    Charles Harris
    Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, California 94158, USA
    J Biol Chem 286:42615-25. 2011
    Steatosis is a frequent complication of hepatitis C virus infection. In mice, this condition is recapitulated by the expression of a single viral protein, the nucleocapsid core...
  64. pmc Control of innate immune signaling and membrane targeting by the Hepatitis C virus NS3/4A protease are governed by the NS3 helix α0
    Stacy M Horner
    Department of Immunology, University of Washington, Seattle, Washington, USA
    J Virol 86:3112-20. 2012
    b>Hepatitis C virus (HCV) infection is sensed in the host cell by the cytosolic pathogen recognition receptor RIG-I. RIG-I signaling is propagated through its signaling adaptor protein MAVS to drive activation of innate immunity...
  65. pmc New insights regarding HCV-NS5A structure/function and indication of genotypic differences
    Lilian Ht Yamasaki
    Department of Biology, Sao Paulo State University UNESP, Sao Jose do Rio Preto, SP, Brazil
    Virol J 9:14. 2012
    b>HCV is prevalent throughout the world. It is a major cause of chronic liver disease. There is no effective vaccine and the most common therapy, based on Peginterferon, has a success rate of ~50%...
  66. pmc The C terminus of NS5A domain II is a key determinant of hepatitis C virus genome replication, but is not required for virion assembly and release
    Douglas Ross-Thriepland
    School of Molecular and Cellular Biology, Faculty of Biological Sciences and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK
    J Gen Virol 94:1009-18. 2013
    The NS5A protein of hepatitis C virus (HCV) plays roles in both virus genome replication and the assembly of infectious virus particles. NS5A comprises three domains, separated by low-complexity sequences...
  67. doi HIV-1 Nef interacts with HCV Core, recruits TRAF2, TRAF5 and TRAF6, and stimulates HIV-1 replication in macrophages
    Kashif A Khan
    Department of Virology, UPRES EA4266 Pathogens and Inflammation, SFR FED 4234, University of Franche Comte, CHU Besancon, Besancon, France
    J Innate Immun 5:639-56. 2013
    ..of apoptosis, which are key events in the pathogenesis of the human immunodeficiency virus (HIV)-1 and the hepatitis C virus (HCV) infections...
  68. pmc Dynamic imaging of the hepatitis C virus NS5A protein during a productive infection
    Nicholas S Eyre
    School of Molecular and Biomedical Science and Centre for Molecular Pathology, University of Adelaide, Adelaide, South Australia, Australia
    J Virol 88:3636-52. 2014
    b>Hepatitis C virus (HCV) NS5A is essential for viral genome replication within cytoplasmic replication complexes and virus assembly at the lipid droplet (LD) surface, although its definitive functions are poorly understood...
  69. pmc Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2
    Abdul Ghafoor Khan
    Center for Advanced Biotechnology and Medicine, Department of Chemistry and Chemical Biology, Rutgers University, 679 Hoes Lane West, Piscataway, New Jersey 08854, USA
    Nature 509:381-4. 2014
    b>Hepatitis C virus (HCV) is a significant public health concern with approximately 160 million people infected worldwide. HCV infection often results in chronic hepatitis, liver cirrhosis and hepatocellular carcinoma...
  70. pmc Interaction between hepatitis C virus core protein and E1 envelope protein
    S Y Lo
    Department of Molecular Microbiology and Immunology, University of Southern California, Los Angeles 90033, USA
    J Virol 70:5177-82. 1996
    b>Hepatitis C virus has three structural genes named C, E1, and E2. The C gene encodes the core (capsid) protein and the E1 and E2 genes encode the envelope proteins...
  71. ncbi Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA
    A A Kolykhalov
    Department of Molecular Microbiology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110 1093, USA
    Science 277:570-4. 1997
    More than 1% of the world's population is chronically infected with hepatitis C virus (HCV)...
  72. ncbi Specific in vitro association between the hepatitis C viral genome and core protein
    Z Fan
    Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Canada
    J Med Virol 59:131-4. 1999
    ..These data suggest that there is a specific interaction between the 5'NCR of the hepatitis C virus (HCV) genome and HCV core protein...
  73. ncbi Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP
    A K Ghosh
    Department of Pathology, Saint Louis University, St Louis, Missouri 63104, USA
    J Biol Chem 275:7184-8. 2000
    b>Hepatitis C virus NS5A protein transcriptionally modulates cellular genes and promotes cell growth. NS5A is likely to exert its activity in concert with cellular factor(s)...
  74. pmc Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR
    Stefan Pohlmann
    Department of Microbiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Virol 77:4070-80. 2003
    ..We found that soluble versions of the hepatitis C virus (HCV) E2 glycoprotein and retrovirus pseudotypes expressing chimeric forms of both HCV E1 and E2 ..
  75. pmc Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication
    Matthew J Evans
    Integrated Program in Cellular, Molecular, and Biophysical Studies, Department of Biochemistry and Biophysics, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 101:13038-43. 2004
    The study of the hepatitis C virus (HCV) has been hindered by the lack of in vitro model systems...
  76. ncbi Hepatitis C virus (HCV) NS5A protein downregulates HCV IRES-dependent translation
    Katerina I Kalliampakou
    Molecular Virology Laboratory, Hellenic Pasteur Institute, 127 Vas Sofias Avenue, Athens 115 21, Greece
    J Gen Virol 86:1015-25. 2005
    Translation of the hepatitis C virus (HCV) polyprotein is mediated by an internal ribosome entry site (IRES) that is located mainly within the 5' non-translated region of the viral genome...
  77. ncbi Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication
    Chunfu Wang
    Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Mol Cell 18:425-34. 2005
    We recently reported that Hepatitis C virus (HCV) RNA replication requires one or more geranylgeranylated host proteins...
  78. ncbi Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase
    Koichi Watashi
    Laboratory of Human Tumor Viruses, Department of Viral Oncology, Institute for Virus Research, Kyoto University, Kyoto 606 8507, Japan
    Mol Cell 19:111-22. 2005
    ..cis-trans isomerase (PPIase), cyclophilin B (CyPB), is critical for the efficient replication of the hepatitis C virus (HCV) genome...
  79. ncbi Trans-complementation of HCV replication by non-structural protein 5A
    Xiao Tong
    Virology Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Virus Res 115:122-30. 2006
    Although establishment of the subgenomic replicon system has considerably facilitated genetic analysis of HCV replication, many details remain largely unknown...
  80. ncbi Identification of glycosaminoglycan-binding sites within hepatitis C virus envelope glycoprotein E2*
    L V Olenina
    Institute of Biomedical Chemistry RAMS, Moscow, Russia
    J Viral Hepat 12:584-93. 2005
    Heparan sulphate is one of the candidate receptors for hepatitis C virus (HCV). Envelope glycoproteins of HCV have been proposed to be responsible for recognition and binding with cell receptors...
  81. pmc RNA translocation and unwinding mechanism of HCV NS3 helicase and its coordination by ATP
    Sophie Dumont
    Biophysics Graduate Group, University of California, Berkeley, California 94720, USA
    Nature 439:105-8. 2006
    ..in real time, at a resolution of two base pairs and 20 ms, the RNA translocation and unwinding cycles of a hepatitis C virus helicase (NS3) monomer...
  82. ncbi The protein phosphatase 2A represents a novel cellular target for hepatitis C virus NS5A protein
    Urania Georgopoulou
    Molecular Virology Laboratory, Hellenic Pasteur Institute, 127, Vas Sofias Avenue, Athens 11521, Greece
    Biochimie 88:651-62. 2006
    It is well established that HCV NS5A protein when expressed in mammalian cells perturbs the extracellular signal regulated kinase (ERK) pathway...
  83. pmc Core protein cleavage by signal peptide peptidase is required for hepatitis C virus-like particle assembly
    Malika Ait-Goughoulte
    INSERM ESPRI 3856, IFR 136, Universite Francois Rabelais, Faculté de Médecine and CHU, 10 boulevard Tonnelle, 37032 Tours, France
    J Gen Virol 87:855-60. 2006
    b>Hepatitis C virus (HCV) core protein, expressed with a Semliki Forest virus replicon, self-assembles into HCV-like particles (HCV-LP) at the endoplasmic reticulum (ER) membrane, providing an opportunity to study HCV assembly and ..
  84. pmc Oligomerization of hepatitis C virus core protein is crucial for interaction with the cytoplasmic domain of E1 envelope protein
    Kousuke Nakai
    Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, 3 1, Yamadaoka, Suita, Osaka 565 0871, Japan
    J Virol 80:11265-73. 2006
    b>Hepatitis C virus (HCV) contains two membrane-associated envelope glycoproteins, E1 and E2, which assemble as a heterodimer in the endoplasmic reticulum (ER)...
  85. ncbi Mutagenesis of a conserved fusion peptide-like motif and membrane-proximal heptad-repeat region of hepatitis C virus glycoprotein E1
    Heidi E Drummer
    Macfarlane Burnet Institute for Medical Research and Public Health Ltd, GPO Box 2284, Melbourne 3001, Australia
    J Gen Virol 88:1144-8. 2007
    The E1E2 glycoprotein heterodimer of Hepatitis C virus mediates viral entry. E2 attaches the virus to cellular receptors; however, the function of E1 is unknown. We tested the hypothesis that E1 is a truncated class II fusion protein...
  86. ncbi Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha
    Yi Zhou
    Vertex Pharmaceuticals Inc, Cambridge, Massachusetts 02139, USA
    J Biol Chem 282:22619-28. 2007
    Telaprevir (VX-950) is a highly selective, potent inhibitor of the hepatitis C virus (HCV) NS3.4A serine protease...
  87. pmc Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding
    Kathleen McCaffrey
    Macfarlane Burnet Institute for Medical Research and Public Health, 85 Commercial Rd, Melbourne, Australia
    J Virol 81:9584-90. 2007
    The hepatitis C virus glycoprotein E2 receptor-binding domain is encompassed by amino acids 384 to 661 (E2(661)) and contains two hypervariable sequences, HVR1 and HVR2...
  88. doi Expression studies of the HCV-1a core+1 open reading frame in mammalian cells
    Niki Vassilaki
    Molecular Virology Laboratory, Hellenic Pasteur Institute, 127 Vas Sofias Avenue, 11521 Athens, Greece
    Virus Res 133:123-35. 2008
    The hepatitis C virus (HCV) genome possesses an open reading frame overlapping the core gene in the +1 frame (core+1 ORF)...
  89. pmc NS3 helicase domains involved in infectious intracellular hepatitis C virus particle assembly
    Yinghong Ma
    Center for Hepatitis Research, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555 1073, USA
    J Virol 82:7624-39. 2008
    A mutation within subdomain 1 of the hepatitis C virus (HCV) NS3 helicase (NS3-Q221L) (M. Yi, Y. Ma, J. Yates, and S. M. Lemon, J. Virol...
  90. doi The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism
    Ya Hui Tsai
    Graduate Institute of Microbiology, National Taiwan University College of Medicine, Taipei 100, Taiwan
    J Hepatol 49:899-907. 2008
    Patients infected with hepatitis C virus (HCV) genotype 2 or 3 usually respond better to interferon (IFN) treatment than those infected with genotype 1...
  91. doi HCV envelope protein function is dependent on the peptides preceding the glycoproteins
    Tao Bian
    National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Yingxin Street 100, Xuanwu Distract, Beijing 100052, PR China
    Biochem Biophys Res Commun 378:118-22. 2009
    Although significant advances have been made on the studies of HCV glycoproteins (E1 and E2) recently, the role of the peptides preceding each glycoprotein remains unclear...
  92. doi Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded
    Xavier Hanoulle
    UGSF, UMR CNRS, IFR, Universite des Sciences et Technologies de Lille, Villeneuve d Ascq, France
    Biochem Biophys Res Commun 381:634-8. 2009
    b>Hepatitis C virus (HCV) non-structural protein 5A (NS5A) is involved both in the viral replication and particle production...
  93. doi Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus
    Qingxia Han
    State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People s Republic of China
    Virus Res 145:63-73. 2009
    In this study, an infectious HCV monocistronic reporter virus was constructed by inserting an EGFP gene into the C-terminus of NS5A in the JFH-1 genome...
  94. pmc Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry
    Hsiao Fen Li
    Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan
    J Biomed Sci 16:89. 2009
    Envelope (E) glycoprotein E2 of the hepatitis C virus (HCV) mediates binding of the virus to target cell receptors. Nevertheless, the precise role of E1 in viral entry remains elusive.
  95. doi A single point mutation in E2 enhances hepatitis C virus infectivity and alters lipoprotein association of viral particles
    Wanyin Tao
    Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 225 South Chongqing Road, Shanghai, China
    Virology 395:67-76. 2009
    b>Hepatitis C virus (HCV) infection is a major worldwide health problem. Our previous results showed that HCV evolved to gain the enhanced infectivity and altered buoyant density distribution during persistent infections in vitro...
  96. doi Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory
    Jérôme Gouttenoire
    Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    Rev Med Virol 20:117-29. 2010
    b>Hepatitis C virus (HCV) is a positive-strand RNA virus that replicates its genome in a membrane-associated replication complex...
  97. pmc Kinetic analysis of the nucleic acid chaperone activity of the hepatitis C virus core protein
    Kamal Kant Sharma
    Laboratorie de Biophotonique et Pharmacologie, UMR 7213 CNRS, Faculte de Pharmacie, Universite de Strasbourg, 74, route du Rhin, 67401, Illkirch, Cedex, France
    Nucleic Acids Res 38:3632-42. 2010
    The multifunctional HCV core protein consists of a hydrophilic RNA interacting D1 domain and a hydrophobic D2 domain interacting with membranes and lipid droplets...
  98. doi Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells
    Valerio Pazienza
    Gastroenterology Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo FG, Italy
    J Gen Virol 91:1678-86. 2010
    b>Hepatitis C virus (HCV) core protein genotype 3a induces the expression of suppressor of cytokine signalling protein 7 (SOCS-7), which is partially involved in the development of insulin resistance...
  99. pmc Dimerization-driven interaction of hepatitis C virus core protein with NS3 helicase
    G Mousseau
    Department of Infectology, The Scripps Research Institute, Scripps Florida, 130 Scripps Way, 3C1, Jupiter, FL 33458, USA
    J Gen Virol 92:101-11. 2011
    b>Hepatitis C virus (HCV) infects over 130 million people causing a worldwide epidemic of liver cirrhosis and hepatocellular-carcinoma...
  100. pmc Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins
    Yinghong Ma
    Department of Microbiology and Immunology, The University of Texas Medical Branch at Galveston, 301 University Boulevard, Galveston, TX 77555 0610, USA
    J Virol 85:86-97. 2011
    Many aspects of the assembly of hepatitis C virus (HCV) remain incompletely understood...
  101. pmc Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication
    Kristi L Berger
    Department of Microbiology, The University of Chicago, Chicago, IL 60637, USA
    J Virol 85:8870-83. 2011
    Phosphatidylinositol 4-kinase III alpha (PI4KA) is an essential cofactor of hepatitis C virus (HCV) replication. We initiated this study to determine whether HCV directly engages PI4KA to establish its replication...

Research Grants95

  1. GUANGXIANG GEORGE LUO; Fiscal Year: 2016
    ..goal of this application is to determine the importance of the cellular protein apolipoprotein E (apoE) in hepatitis C virus (HCV) infection and production in vivo and to define the underlying molecular mechanism of apoE in HCV ..
  2. GUANGXIANG GEORGE LUO; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection continues to be a major burden on public health, affecting approximately 170 million people worldwide and 3-4 million Americans...
  3. Effects of Ethanol on Proteasome-HCV Core Protein Interactions
    NATALIA ALEKSANDR OSNA; Fiscal Year: 2010
    ..Lay Language Summary: The proposed study will expand our knowledge in the mechanisms of how hepatitis C viral protein and ethanol regulate the enzyme, which degrades proteins...
  4. Hepatitis C and Tumor Suppressors in Hepatocellular
    Stanley M Lemon; Fiscal Year: 2011
    ..the clinical relevance and potential role in hepatic carcinogenesis of interactions between host cell and hepatitis C virus (HCV) proteins that have been identified in previous cell culture-based experiments...
  5. Steven A Weinman; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): The combination of Hepatitis C virus (HCV) infection and alcohol consumption produces a more severe liver disease than either condition alone with increased rates of both cirrhosis and hepatocellular ..
  6. Warren N Schmidt; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Hepatitis C (HCV) is a major cause of cirrhosis and considerable morbidity worldwide...
  7. Urtzi Garaigorta; Fiscal Year: 2015
    ..together with our collaborators at the Salk Institute, we have recently demonstrated efficient HBV and hepatitis C virus infection in a novel chimeric mouse model repopulated with human hepatocytes that allows us to study all ..
  8. Peter Sarnow; Fiscal Year: 2016
    ..carcinoma, a leading cause of cancer-related deaths, is caused by infection with either hepatitis B or hepatitis C virus (HCV)...
  9. Swati Joshi-Barve; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Chronic Hepatitis C virus (HCV) infection remains a global health concern with nearly 200 million carriers worldwide...
  10. Mechanisms of Cellular Immune Dysfunction in Patients with Hepatitis C Virus and
    Kyong Mi Chang; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is a blood-borne, hepatotropic RNA virus with a high propensity for chronic infection that can progress to cirrhosis and liver cancer...
  11. SAMUEL WHEELER FRENCH; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection has a worldwide prevalence of 3% and is the main entity responsible for liver transplantation in developed countries for treatment of cirrhosis...
  12. Inflammation, Stress, and Social Behavior: Using Ecological Assessments and Model
    Charles Raison; Fiscal Year: 2012
    ..To test these hypotheses, 120 subjects with chronic hepatitis C virus infection will be randomized to receive treatment with pegylated IFN-alpha plus ribavirin or to postpone ..
  13. Stanley M Lemon; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is a major cause of liver-specific morbidity and mortality worldwide, resulting in >350,000 deaths annually due to cirrhosis and cancer with high rates of disease among ..
  14. Phase I/II Trials of Silymarin for Chronic Liver Diseases Data Coordinating Cente
    Steven H Belle; Fiscal Year: 2011
    ..There is a potential role for silymarin, particularly for treating patients with chronic hepatitis C virus who have contraindications to therapy with interferon and ribavirin...
  15. Backbone Modified Peptide-nucleic Acids as Antiviral Agents Against Hepatitis C
    MIHAELA R MIHAILESCU; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): With more than 200 million people infected, the Hepatitis C virus (HCV) poses a major health problem worldwide...
  16. Hepatocarcinogenesis Secondary to Hepatitis C
    Srikanta Dash; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is a major public health problem with more than 170 millions people are currently infected. Most infections become chronic often leading to liver cirrhosis and cancer...
  17. Hepatitis C Virus Quasispecies in the Resistance to Antiviral Therapy
    Xiaofeng Fan; Fiscal Year: 2012
    Project Summary Hepatitis C virus (HCV) infection is one of the major concerns in public health...
  18. Role of HCV p7 and NS2 in infectious virus production
    Charles M Rice; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is the etiologic agent of parenterally transmitted non-A, non-B viral hepatitis...
  19. Listeria-Based Therapeutic Cancer Vaccine for Melanoma
    Dirk G Brockstedt; Fiscal Year: 2011
    ..were dosed safely with up to 1 x 109 live-attenuated bacteria for the treatment of advanced cancers and chronic hepatitis C infections...
  20. Phase I Clinical Study Using an Antifibrotic Drug
    Weizhong Cai; Fiscal Year: 2011
    ..from complications of liver fibrosis/cirrhosis are expected to triple over the next decade as a result of the hepatitis C epidemic and the growing incidence of liver disease associated with non-alcoholic steatohepatitis...
  21. HCV in Alcoholics
    Jack R Wands; Fiscal Year: 2011
    Chronic hepatitis C (HCV) infection is a major cause of liver disease, cirrhosis, and hepatocellular carcinoma (HCC) in alcoholics...
  22. BRIAN JAMES MCMAHON; Fiscal Year: 2016
    ..11] In addition to chronic HBV, other chronic liver disease etiologies including chronic hepatitis C, non- alcoholic fatty liver disease and autoimmune hepatitis have been shown to cause substantial morbidity and ..
  23. Liana Fraenkel; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): Project Summary Chronic hepatitis C (HCV) is a major healthcare burden among American veterans...
  24. Ribavirin depletes endogenous nucleotide pools
    JENNIFER JUSTICE KISER; Fiscal Year: 2013
    ..antiviral drugs available in the world, and it is a fundamental component of treatment for chronic Hepatitis C virus (HCV)...
  25. Bachir Taouli; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): There is an expected increased incidence of chronic hepatitis C virus infection (HCV) in the Unites States within the next years, with subsequent increased risks of liver damage, including fibrosis ..
  26. Srikanta Dash; Fiscal Year: 2016
    ..mechanisms suggesting that type III interferon system plays a very important role in the clearance of hepatitis C virus infection...
  27. Mechanistic Studies of HCV E2
    Joseph Marcotrigiano; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection is a causal agent of chronic liver disease in humans, afflicting more than 123 million people worldwide (approximately 2% of the human population)...
  28. YPE PETER DE JONG; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is a RNA virus that chronically infects ~3% of the world population leading to cirrhosis and/or hepatocellular carcinoma in ~20% of those infected...
  29. Raymond T Chung; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Chronic hepatitis C and B are important and growing causes of morbidity and mortality in the United States...
  30. Cost-effective Uses of New Hepatitis C Treatments and their VA Budgetary Impact
    Douglas K Owens; Fiscal Year: 2013
    ..long-term goals of our research are to: 1) help VA clinicians improve outcomes for veterans with chronic, hepatitis C virus (HCV) infections using treatment regimens that may incorporate newly available, directly acting antivirals (..
  31. Concentration-Controlled Ribavirin for the Treatment of Patients with Chronic HVC
    JENNIFER JUSTICE KISER; Fiscal Year: 2013
    ..Pharmacology research in chronic Hepatitis C virus (HCV) is urgently needed because of the poor response rates with current therapies and the need to ..
  32. Michael A Gelman; Fiscal Year: 2015
    ..disciplines and whose long-term career goal is a position in academic medicine, proposes to study the hepatitis C virus using a novel class of small molecules, the PI4K inhibitors...
  33. Lishan Su; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Chronic hepatitis C virus (HCV) infection is now the leading cause of hepatocellular carcinoma (HCC), a highly lethal cancer with rapidly increasing incidence in the U.S...
  34. Charles M Rice; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide (1) and is the major indication for liver transplantation in the United States (2, 3)...
  35. Susan L Uprichard; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infects more than 180 million people worldwide, causing acute and chronic hepatitis and hepatocellular carcinoma, however, no protective vaccine is available and only a subset ..
  36. Role for tissue-type plasminogen activator in suppression of hepatic fibrosis
    Liang I Kang; Fiscal Year: 2013
    ..With the dramatic increased prevalence of non-alcoholic fatty liver disease and chronic hepatitis C worldwide, it is expected that the health care impact and cost of liver cirrhosis will dramatically increase in ..
  37. Michael W Fried; Fiscal Year: 2014
    ..Over the last decade, significant progress has occurred in the development of new treatments for chronic hepatitis C and hepatitis B, although management strategy of these diseases continues to evolve...
  38. The Molecular Mechanism of Antibody Neutralization of Hepatitis C Virus
    Michelle Sabo; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Hepatitis C virus is a chronic, viral disease that infects the liver...
  39. Structure and function of the HCV RNA replicase
    Charles M Rice; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is the etiologic agent of parenterally transmitted non-A, non-B viral hepatitis...
  40. DONNA LORRAINE WHITE; Fiscal Year: 2014
    ..S. The leading cause of cirrhosis is the hepatitis C virus infection which affects more than 4 million Americans...
  41. Mechanisms and Functions of Core-induced Lipid Droplet Accumulation in Hepatitis
    MELANIE MARIA OTT; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Infection with Hepatitis C Virus (HCV) is a global health problem affecting ~2 percent of the world's population...
  42. Safety and PK Study in Hepatic Impairment Patients
    Weizhong Cai; Fiscal Year: 2010
    ..from complications of liver fibrosis/cirrhosis are expected to triple over the next decade as a result of the hepatitis C epidemic and the growing incidence of liver disease associated with non-alcoholic steatohepatitis...
  43. Hepatic Lipase and HCV Infection
    Tianyi Wang; Fiscal Year: 2010
    b>Hepatitis C virus (HCV) infects 170 million people worldwide and exacts a heavy toll on global health. Diseases caused by chronic HCV infection include acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma...
  44. Interferon modulation of cellular microRNAs in the Hepatitis C antiviral defense
    Michael David; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Worldwide, approximately 2% of the population is infected with Hepatitis C virus (HCV) and 50-80% of those develops into persistent infections and are at great risk of developing hepatocellular ..
  45. Role of HCV Sequence Variation in Pathology
    John E Tavis; Fiscal Year: 2010
    Chronic Hepatitis C virus (HCV) infection causes hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma. The factors governing the rate of disease progression along this spectrum of pathology are not known...
  46. DINUCLEOTIDE ISOMER AS A NOVEL ANTIVIRAL
    Radhakrishnan P Iyer; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Acute and chronic liver infections caused by Hepatitis C virus (HCV) constitute a major worldwide public health crisis with significant unmet medical need...
  47. Roles for RCK/DDX6 in hepatitis C virus pathogenesis and hepatocellular carcinoma
    Peter Sarnow; Fiscal Year: 2010
    ..alcohol abuse or environmental toxins, approximately 80% are caused by infection with either hepatitis B or hepatitis C virus (HCV)...
  48. Molecular mechanism of cellular activation of the hepatitis C virus polymerase
    Julie Akiko Heck; Fiscal Year: 2010
    ..DESCRIPTION (provided by applicant): 2-3% of the world's population is estimated to be infected with the hepatitis C virus (HCV), the etiological agent of non-A, non-B hepatitis...
  49. Isolation of Genetic Suppressor Elements Against Hepatitis C Virus
    Zhilei Chen; Fiscal Year: 2010
    b>Hepatitis C virus (HCV) infection is a major public health problem, putting infected individuals (~180 million worldwide) at risk of developing cirrhosis, hepatocellular carcinoma, and liver failure...
  50. Advancing clemizole for hepatitis C: towards a pre-IND package
    Jeffrey S Glenn; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate...
  51. Interactions Between Hepatitis C and Serum Lipid Homeostasis
    KATHLEEN COREY; Fiscal Year: 2010
    ..More than 4 millions Americans have hepatitis C virus (HCV) infection and 75% develop chronic disease, significantly impacting the health of our community...
  52. Mechanism of murine coronavirus induced hepatitis
    Susan R Weiss; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Hepatitis C and hepatitis B virus infections in humans are characterized by hepatocellular necrosis, inflammation, and development of hepatoma...
  53. Intracellular immunization strategy in inhibit HCV related liver cancer
    Srikanta Dash; Fiscal Year: 2010
    ..strategy with a genetically engineered human antibody clone as a novel antiviral therapy against the hepatitis C virus. This antibody clone targets the HCV NS3 protein, which has multiple enzymatic activities (protease, ..
  54. Hepatitis C Clinical Trial-Clinical Center
    Jules L Dienstag; Fiscal Year: 2009
    Patients with chronic hepatitis C who do not respond to antiviral treatment are at risk of progression to cirrhosis, liver failure, hepatocellular carcinoma (HCC) and death...
  55. Hepatitis C virus and liver fibrogenesis
    Gulam Waris; Fiscal Year: 2010
    ..applicant): The major goal of this proposal is to understand the molecular mechanism(s) of liver fibrosis by hepatitis C virus (HCV) infection. Hepatitis C virus (HCV) is the leading cause of chronic liver disease worldwide...
  56. PDGFR and KDR Inhibitors for Liver Fibrosis
    Bert Oehlen; Fiscal Year: 2010
    ..from complications of liver fibrosis/cirrhosis are expected to triple over the next decade as a result of the hepatitis C epidemic and the growing incidence of liver disease associated with non-alcoholic steatohepatitis...
  57. PHILIPPE ANDRE GALLAY; Fiscal Year: 2014
    ..PUBLIC HEALTH RELEVANCE: An estimated 170 million people worldwide are chronically infected with Hepatitis C virus. 10-20% of these will develop cirrhosis and 1-5% will develop hepatocellular carcinoma...
  58. Prevention of Complications in Thalassemia
    Elliott P Vichinsky; Fiscal Year: 2011
    ..Transfused patients are also screened annually for hepatitis C surface antibody and if positive, PCR for hepatitis C is measured...
  59. Genotyping and Phenotyping the Hepatitis C Drug Target NS5A
    ROBERT T STRIKER; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): AIMS: Hepatitis C Virus (HCV) harms a substantial number of Veterans Administration (VA) patients, and therapy is complicated by many different strains of the virus...
  60. Brett D Lindenbach; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is a major cause of acute and chronic liver disease, and contributes to the development of hepatocellular carcinoma...
  61. Patient self-management and gene guided therapy for CHC
    Donald E Bailey; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Treatment for chronic hepatitis C (CHC) will undergo a dramatic change this year when a new blood test for a genetic polymorphism near the interleukin 28B (IL28B) gene and two newly approved protease ..
  62. PHILIPPE ANDRE GALLAY; Fiscal Year: 2014
    ..C5A corresponds to a small (18 amino acids) N-terminal region (aa 3-20) of the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) (477 amino acids)...
  63. Interaction of HSV-2 in Veterans with Chronic Hepatitis C Co-Infection
    Mary Jane Burton; Fiscal Year: 2013
    ..clinical trial evaluating the effect of HSV-2 suppression on HCV viral load in patients with genotype 1 hepatitis C virus and herpes simplex type-2 co-infection...
  64. Jack T Stapleton; Fiscal Year: 2016
    ..In addition, hepatitis C virus is an accepted risk for NHL, and GBV-C is closely related to HCV, sharing considerable amino acid homology (..
  65. A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus
    Boro Dropulic; Fiscal Year: 2009
    ..interest and/or be pseudotyped with glycoproteins from a large host of families of enveloped viruses;E1E2 of hepatitis C virus, prM and E of yellow fever virus, prM and E of West Nile virus, E of Dengue virus and HA of influenza virus ..
  66. EXPERIMENTAL MODELS AND CLINICAL VIROLOGY OF HEPATITIS C
    Nelson Fausto; Fiscal Year: 1999
    ..HCV infection is characterized by persistent viremia and often progressive liver disease. Chronic hepatitis C is the most common indication for liver transplantation in adults, and at the University of Washington Medical ..
  67. Targeting pDCs for the Generation of Effective Anti-HCV CD8+ T-Cell Immunity
    John Connolly; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection represents a significant global health-care problem, which is forecasted to become worse in the coming years...
  68. Intrahepatic IRF-3 and NF-kB Signaling and Interferon Responses in Hepatitis C
    Stanley M Lemon; Fiscal Year: 2010
    ..Research project focuses on developing a better understanding of the interactions of hepatitis C virus (HCV) with host innate antiviral response systems within the liver of infected persons...
  69. Oxidative damage and proteasome activity: Role of opioid in HIV-HCV infection
    Nazira El Hage; Fiscal Year: 2010
    Among injection drug users (IDUs), human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are the two blood-borne pathogens most commonly transmitted...
  70. Hepatitis C Virus, Alcohol and Host Defense
    Gyongyi Szabo; Fiscal Year: 2007
    ..DESCRIPTION (provided by applicant): Alcohol use accelerates the progression of liver disease in chronic hepatitis C (HCV) infection; however, the interactions between alcohol and HCV have not yet been explored...
  71. Incident HIV Infection and Immune Response to Hepatitis C Virus
    Andrea Cox; Fiscal Year: 2007
    ..years working with her mentors, Drs Thomas, Ray, and Pardoll on the cellular and humoral immune responses to hepatitis C virus (HCV) infection. Through this award, Dr...
  72. Structure and Function of the Hepatitis C Virus Genome
    PETER contact SARNOW; Fiscal Year: 2010
    ..carcinoma, a leading cause of cancer-related deaths, is caused by infection with either hepatitis B or hepatitis C virus (HCV)...
  73. Cell Culture System for Hepatitis C Virus Genotype 1a
    Adrian Di Bisceglie; Fiscal Year: 2009
    b>Hepatitis C virus (HCV) results in persistent infection in up to 80% of infected individuals and causes a wide spectrum of liver diseases...
  74. Heme Oxygenase-1 and Hepatitis C
    Warren Schmidt; Fiscal Year: 2006
    b>Hepatitis C virus (HCV) is a global health problem, causing chronic hepatitis, cirrhosis, and hepatocellular carcinoma, superoxide and peroxide that arise during viral infection and damage hepatocytes and surrounding cells...
  75. HEPATITIS C VIRUS IN ETIOLOGY OF WA RHEUMATOID FACTORS
    Vincent Agnello; Fiscal Year: 2001
    We have established the association of hepatitis C virus (HCV) infection with type II cryoglobulinemia (MC-II) and with the WA crossidiotype (XId) positive monoclonal rheumatoid factors (WA mRF), and the selective concentration of HCV ..
  76. Hepatitis C: Studies of Immunity and Pathogenesis
    Charles Rice; Fiscal Year: 2009
    b>Hepatitis C virus (HCV) is an important cause of chronic liver disease, cirrhosis and cancer. Its limited host range (humans and chimpanzees) and poor replication in cell culture have made it difficult to study...
  77. Structural and Functional Studies of Hepatitic C Core and NS4B Proteins
    Daniel Calarese; Fiscal Year: 2009
    Currently, it is estimated up to 150-200 million people may be infected Hepatitis C virus (HCV). Chronic HCV infection can lead to a variety of liver-related diseases, such as liver cirrhosis and hepatocellular carcinoma...
  78. The Role of PD-1 and SOCS-1 in regulating T cell responses in HCV infection
    Jonathan Moorman; Fiscal Year: 2007
    ..PD-1) and suppressor of cytokine signaling-1 (SOCS-1), in regulation of T cell responses during chronic hepatitis C virus (HCV) infection...
  79. The role of PD-1 and SOCS-1 in HCV core/gC1qR-mediated IL-12 suppression
    Zhi Yao; Fiscal Year: 2009
    ..PUBLIC HEALTH RELEVANCE: Chronic hepatitis C viral infection is a global epidemic with poor treatment options...
  80. Hepatitis C Virus Replication and Intracellular Membrane Rearrangement
    Kouacou Konan; Fiscal Year: 2009
    b>Hepatitis C virus (HCV) is a leading cause of liver cancer worldwide. During infection, HCV induces the formation of rearranged membrane structures termed web...
  81. HEPATITIS C IN CLINICALLY DISCORDANT HEMOPHILIC SIBLINGS
    Michael Fried; Fiscal Year: 2002
    The clinical spectrum of hepatitis C is variable and the factors responsible for these divergent outcomes with chronic hepatitis C infection remain unknown...
  82. DECREASING SEVERITY OF RECURRENT HEPATITIS C IN LIVER
    Lakshmi Gaur; Fiscal Year: 1999
    Based on observations we have recently made, there is evidence that the recurrence of hepatitis C virus (HCV)-induced liver disease in transplanted livers may be reduced by the careful selection of the donor...
  83. DETERMINANTS OF HEPATITIS C & E MORBIDITY IN EGYPT
    George Strickland; Fiscal Year: 2004
    ..virological techniques, Non-A Non-B hepatitis patients have now been categorized into those infected with hepatitis C virus (HCV), a parenterally transmitted flavivirus, and hepatitis E virus (HEV), a fecal-oral transmitted "..
  84. DETERMINANTS OF HEPATITIS C & E MORBIDITY IN EGYPT
    George Strickland; Fiscal Year: 2002
    ..virological techniques, Non-A Non-B hepatitis patients have now been categorized into those infected with hepatitis C virus (HCV), a parenterally transmitted flavivirus, and hepatitis E virus (HEV), a fecal-oral transmitted "..
  85. Innate Control of Hepatitis C Virus Infection: Antiviral and Evasion Mechanisms
    FRANCIS CHISARI; Fiscal Year: 2009
    The long term goal of these studies is to define the innate host-virus interactions that occur during hepatitis C virus (HCV) infection with the hope that this will lead to novel therapeutic approaches to this disease...
  86. Cis-acting RNA elements in hepatitis C virus replication
    Guangxiang Luo; Fiscal Year: 2007
    b>Hepatitis C virus (HCV) is the major etiologic agent of non-A, non-B (NANB) viral hepatitis, infecting approximately 4 million people in the U.S...
  87. Stabilize Addiction/Affect, Begin Inmates' Interferon for HCV of Liver (STAABIHL)
    Peter Friedmann; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): The co-occurrence of chronic hepatitis C virus (HCV) infection, drug dependence and psychiatric disorders is one of the greatest public health challenges to the incarcerated population...
  88. Integrated Desktop Software for Management of Hepatitic C Data
    Johanna C Craig; Fiscal Year: 2010
    The hepatitis C virus (HCV) infects approximately 4 million people in the U.S...

Patents98

  1. 2'-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION
    Patent Number: JP2016136946-A; Date:2016-08-04
  2. Hepatitis C virus core targeting trans-splicing ribozyme and use thereof
    Patent Number: KR1020160038859-A; Date:2016-04-07
  3. NEW INHIBITORS OF CYCLOPHILINS AND USES THEREOF
    Patent Number: JP2016128488-A; Date:2016-07-14
  4. FLAVIVIRUS REPLICONS
    Patent Number: EP3061826-A1; Date:2016-08-31
  5. A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW& AND HIGH MOLECULAR WEIGHT COMPOUNDS
    Patent Number: EP3001990-A1; Date:2016-04-06
  6. A Pharmaceutical composition for treating and/or preventing Hepatitis C
    Patent Number: WO2016076441-A; Date:2016-05-19
  7. ANTI-HEPATITIS C ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF
    Patent Number: WO2016034891-A1; Date:2016-03-10
  8. FLAVIVIRUS REPLICONS
    Patent Number: WO2016135675-A1; Date:2016-09-01
  9. OPTIMIZED HCV FULL-LENGTH INFECTIOUS CELL CULTURE SYSTEMS AND APPLICATIONS THEREOF
    Patent Number: WO2016066171-A1; Date:2016-05-06
  10. NOVEL FUSION PROTEINS AND USE THEREOF FOR PREPARING HEPATITIS C VACCINES
    Patent Number: KR1020150085128-A; Date:2015-07-22
  11. Conserved HBV and HCV Sequences Useful for Gene Silencing
    Patent Number: JP2015003913-A; Date:2015-01-08
  12. MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND THE USE OF SAME FOR THE DETECTION OF NUCLEIC ACIDS
    Patent Number: KR1020150021493-A; Date:2015-03-02
  13. HEPATITIS C VIRUS VARIANTS
    Patent Number: JP2014217390-A; Date:2014-11-20
  14. Uracyl Spirooxetane Nucleosides
    Patent Number: JP2015518853-A; Date:2015-07-06
  15. Modified oligonucleotides comprising thiol functions and the use of same for the detection of nucleic acids
    Patent Number: JP2015514402-A; Date:2015-05-21
  16. METHOD FOR DETECTING MUTATION OF THE 93rd AMINO ACID OF NS5A PROTEIN OF HEPATITIS C VIRUS, AND KIT FOR DETECTING MUTATION OF THE 93rd AMINO ACID OF NS5A PROTEIN OF HEPATITIS C VIRUS
    Patent Number: WO2015087945-A; Date:2015-06-18
  17. HCV Fusion Polypeptides
    Patent Number: JP2014036675-A; Date:2014-02-27
  18. URACYL SPIROOXETANE NUCLEOSIDES
    Patent Number: KR1020150014457-A; Date:2015-02-06
  19. Structure and Use of 5' Phosphate Oligonucleotides
    Patent Number: JP2014207906-A; Date:2014-11-06
  20. METHOD AND CELLS FOR IDENTIFYING RIG-I PATHWAY REGULATORS
    Patent Number: EP2678019-A2; Date:2014-01-01
  21. FLUORESCENT DYES
    Patent Number: EP2768306-A1; Date:2014-08-27
  22. MUTANT REPLICON DERIVED FROM GENOME OF HEPATITIS C VIRUS J6CF STRAIN
    Patent Number: EP2716757-A1; Date:2014-04-09
  23. INJECTION NEEDLE, DEVICE, IMMUNOGENIC COMPOSITIONS AND METHOD OF USE
    Patent Number: WO2014064534-A2; Date:2014-05-01
  24. Primers and methods for detecting Human Hepatitis C Virus (HCV) variants in an isolated sample
    Patent Number: EP2821508-A1; Date:2015-01-07
  25. MULTIPLEX REAL TIME PCR TESTING KIT FOR THE SIMULTANEOUS DETECTION OF HEPATITIS VIRUS
    Patent Number: WO2014136124-A2; Date:2014-09-12
  26. IDENTIFICATION AND CLONING OF TRANSMITTED HEPATITIC C VIRUS (HCV) GENOMES BY SINGLE GENOME AMPLIFICATION
    Patent Number: EP2788490-A1; Date:2014-10-15
  27. COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS
    Patent Number: EP2688592-A1; Date:2014-01-29
  28. HIGH-TITER HCV FULL-LENGTH GENOTYPE 2B INFECTIOUS CELL CULTURE SYSTEMS AND APPLICATIONS THEREOF
    Patent Number: WO2015014369-A1; Date:2015-02-05
  29. NOVEL HCV CULTURE SYSTEMS AND DIRECT-ACTING ANTIVIRAL SENSITIVITY
    Patent Number: WO2015058772-A2; Date:2015-04-30
  30. CELLULAR VACCINE AND METHOD OF INDUCING AN IMMUNE RESPONSE IN A SUBJECT
    Patent Number: EP2849779-A1; Date:2015-03-25
  31. HCV NS3-NS4A Protease Inhibition
    Patent Number: JP2014237664-A; Date:2014-12-18
  32. 2'-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE MUTATION
    Patent Number: JP2014166183-A; Date:2014-09-11
  33. Quantitative Multiplexed Identification of Nucleic Acid Targets
    Patent Number: JP2014501494-A; Date:2014-01-23
  34. YEAST-BASED THERAPEUTIC VACCINE FOR CHRONIC HEPATITIS C INFECTION AND USE OF THE SAME
    Patent Number: JP2014012679-A; Date:2014-01-23
  35. HEPATITIS C VIRUS VARIANTS
    Patent Number: KR1020140098867-A; Date:2014-08-08
  36. Method for examining and evaluating virus enzymes in hts
    Patent Number: WO2004013349-A2; Date:2004-02-12
  37. Method of screening by using conformation sensitive peptides
    Patent Number: WO2006046134-A2; Date:2006-05-04
  38. Detection and typing of hcv using 5'utr and ns5 nucleic acid sequences
    Patent Number: EP1197568-A2; Date:2002-04-17
  39. Detecting Analytes
    Patent Number: JP2010517026-A; Date:2010-05-20
  40. Method for detecting nucleic acid sequences based on the use of solid phase immobilised nucleotide probes (line probe assay)
    Patent Number: EP0905258-A2; Date:1999-03-31
  41. PARTIAL GENE OF HEPATITIS C VIRUS AND METHOD FOR DETECTING GENE OF HEPATITIS C VIRUS IN HIGH SENSITIVITY
    Patent Number: JP1994153961-A; Date:1994-06-03
  42. HCV VARIANTS
    Patent Number: JP2007143553-A; Date:2007-06-14
  43. A Process for the Detection of Nucleic Acid Using Nucleic Acid
    Patent Number: JP2003525631-A; Date:2003-09-02
  44. Antisense Antiviral Agent and Method for Treating ssRNA Viral Infection
    Patent Number: JP2011147449-A; Date:2011-08-04
  45. Inducing a t cell response with recombinant pestivirus replicons or recombinant pestivirus replicon-transfected dendritic cells
    Patent Number: WO2004092386-A2; Date:2004-10-28
  46. Hepatitis C Virus Particles and Propagation Process Therefor
    Patent Number: WO2006090933-A; Date:2006-08-31
  47. HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS
    Patent Number: JP2008502308-A; Date:2008-01-31
  48. Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids
    Patent Number: JP2008521434-A; Date:2008-06-26
  49. Optimized Multi-epitope Constructs and Uses Thereof
    Patent Number: JP2006501827-A; Date:2006-01-19
  50. Specific and sensitive method for detecting nucleic acids
    Patent Number: WO9923250-A2; Date:1999-05-14
  51. NUCLEIC ACID AMPLIFICATION METHOD
    Patent Number: JP2005508599-A; Date:2005-04-07
  52. METHODS AND DEVICES FOR THE DELIVERY OF PEPTIDES INTO THE GASTRIC
    Patent Number: JP2010508828-A; Date:2010-03-25
  53. Methods of treatment and diagnosis of HCV infection in CNS based on magnetic resonance spectroscopy
    Patent Number: WO0220054-A2; Date:2002-03-14
  54. Methods for the analysis of non-proteinaceous components using a protease from a bacillus strain
    Patent Number: EP1201752-A1; Date:2002-05-02
  55. Method for inhibiting the expression of a target gene
    Patent Number: WO02055693-A2; Date:2002-07-18
  56. Viral and viral associated mirnas and uses thereof
    Patent Number: WO2005116250-A2; Date:2005-12-08
  57. Drug for treating a fibrotic disease through RNA interference
    Patent Number: WO03035083-A1; Date:2003-05-01
  58. A vector for analysis of reproduction system of RNA virus and its use
    Patent Number: WO2001088161-A; Date:2001-11-22
  59. Analysis of hcv genotypes
    Patent Number: WO2010025380-A2; Date:2010-03-04
  60. Hepatitis c dsrna effector molecules, expression constructs, compositions, and methods of use
    Patent Number: EP2173900-A2; Date:2010-04-14
  61. Method of assaying or screening compound via the detection of the inhibition of nuclear transport receptor by hepatitis C virus core protein
    Patent Number: WO2002022812-A; Date:2002-03-21
  62. In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
    Patent Number: JP2011517397-A; Date:2011-06-09
  63. Method for in vitro detection and/or quantification and/or identification of infectious compounds in a biological material
    Patent Number: JP2011511631-A; Date:2011-04-14
  64. METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION
    Patent Number: JP2012520884-A; Date:2012-09-10
  65. In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
    Patent Number: EP2101173-A1; Date:2009-09-16
  66. Use of a double strand ribonucleic acid for treating an infection with a positive-strand rna-virus
    Patent Number: WO03035876-A1; Date:2003-05-01
  67. iRNA CONJUGATES
    Patent Number: JP2013256531-A; Date:2013-12-26
  68. Mutants of hepatitis C virus NS5A protein, and use thereof
    Patent Number: JP2003135078-A; Date:2003-05-13
  69. HCV NS5B PROTEASE MUTANTS
    Patent Number: WO2011159826-A2; Date:2011-12-22
  70. Efficient cell culture system for hepatitis c virus genotype 6a
    Patent Number: WO2009080052-A1; Date:2009-07-02
  71. Method for Screening Remedy for HCV
    Patent Number: JP2003130870-A; Date:2003-05-08
  72. Specific and sensitive method for detecting nucleic acids
    Patent Number: JP2002505071-A; Date:2002-02-19
  73. New screening methods for compounds that are effective in preventing or rescuing hepatocytes from damages caused by hepatitis type C virus infection, and the compounds obtainable with the methods
    Patent Number: WO2001011089-A; Date:2001-02-15
  74. TREATMENT OF AN INFECTION BY AN RNA VIRUS DUE TO AN RNA DEPENDENT RNA POLYMERASE
    Patent Number: JP2009538610-A; Date:2009-11-12
  75. Hcv fusion polypeptides
    Patent Number: WO2008024518-A2; Date:2008-02-28
  76. HCV Fusion Polypeptides
    Patent Number: JP2010501580-A; Date:2010-01-21
  77. Method for production of bioresorbable microparticules, microparticules thus obtained and use thereof
    Patent Number: JP2007521321-A; Date:2007-08-02
  78. Internal de novo initiation sites of the hcv ns5b polymerase and use thereof
    Patent Number: WO0183736-A2; Date:2001-11-08
  79. Tagged oliggonucleotides and their use in nucleic acid amplification methods
    Patent Number: EP2017356-A2; Date:2009-01-21
  80. Recombinant vectors for producing hcv envelope proteins
    Patent Number: EP1211315-A1; Date:2002-06-05
  81. Purified active hcv ns2/3 protease
    Patent Number: WO0248375-A2; Date:2002-06-20
  82. A primary micro rna expression cassette
    Patent Number: WO2008146251-A1; Date:2008-12-04
  83. VIRAL VECTOR CONTAINING GENE CAPABLE OF CODING HEPATITIS C VIRAL CONSTITUENT POLYPEPTIDE INTEGRATED THEREINTO AND METHOD FOR UTILIZING THE SAME
    Patent Number: JP1994141873-A; Date:1994-05-24
  84. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
    Patent Number: JP2004222729-A; Date:2004-08-12
  85. SYSTEM FOR DETECTING POLYNUCLEOTIDES
    Patent Number: JP2007525948-A; Date:2007-09-13
  86. Asymmetric PCR coupled with post-PCR characterization for the identification of nucleic acids
    Patent Number: EP1746172-A2; Date:2007-01-24
  87. A Novel Nucleotide Mixture for Improved Nucleic Acid Amplification Performance
    Patent Number: JP2007518424-A; Date:2007-07-12
  88. PROPAGATION OF HUMAN HEPATOCYTES IN NON-HUMAN ANIMALS
    Patent Number: JP2003512846-A; Date:2003-04-08
  89. CO-EXPRESSION VECTOR FOR THE MEMBRANE DOMAINS OF VIRUS ENVELOPE PROTEINS AND USES THEREOF
    Patent Number: JP2007503804-A; Date:2007-03-01
  90. iRNA CONJUGATES
    Patent Number: JP2006522831-A; Date:2006-10-05
  91. Intracellular Production of Hepatitis C E1 and E2 Truncated Polypeptides
    Patent Number: JP2009232863-A; Date:2009-10-15
  92. iRNA CONJUGATES
    Patent Number: JP2011201887-A; Date:2011-10-13
  93. Nucleic acid construct comprising a nucleic acid derived from the genome of hepatitis C virus of genotype 3a
    Patent Number: WO2013031956-A; Date:2013-03-07
  94. TAGGED OLIGONUCLEOTIDES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION METHODS
    Patent Number: JP2013027408-A; Date:2013-02-07
  95. HUMAN HCV-INTERACTING PROTEINS AND METHODS OF USE
    Patent Number: WO2011015379-A1; Date:2011-02-10
  96. Hepatitis C virus variants
    Patent Number: EP2392589-A2; Date:2011-12-07
  97. Novel hepatitis C E1 and E2 truncated polypeptides and methods of obtaining the same
    Patent Number: EP1510580-A2; Date:2005-03-02
  98. Recombinant live fowlpox virus vectors and their use in pharmaceutical compositions against hepatitis c virus
    Patent Number: WO2006015557-A1; Date:2006-02-16